Cilnidipine demonstrates N-type calcium channel blocking properties and sympatholytic effects in preclinical vascular models, but not selectively in cardiac models.
No takes yet. Share an insight, caveat, or question.
Findings should not alter cilnidipine use in patients; leaves open its vascular sympatholytic effects while challenging selective N-type blockade in vivo.
Nap et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: